INFORMAZIONI SU QUESTO EPISODIO
Major LBT from EuroPCR 2026
This major late-breaking trial from #EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting stents (DES) versus CABG for left main coronary artery disease. Combining long-term data from the EXCEL, NOBLE, PRECOMBAT, and SYNTAX trials, the analysis found remarkably similar mortality outcomes between the two strategies at both 5 and 10 years. David Hildick-Smith and Brian Bergmark discuss how these findings challenge traditional assumptions about the long-term survival advantage of surgery and what they mean for heart team decision-making.
Hosted on Acast. See acast.com/privacy for more information.
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di PCR Perspectives.
ALTRI EPISODI IN QUESTO PODCAST
Hector Garcia joins Salvatore Brugaletta in a discussion on the concept of vulnerable plaque, a key topic in contemporary cardiology. Together, they review the well-established definition of vulnerable plaque, characterised by high-risk features that predispose to rupture and cardiovascular events,…
Javier Escaned and Niels Van Royen explore the evolving role of physiology in coronary assessment, with a focus on angiography-derived and imaging-derived indices, highlighting the growing potential of AI-driven tools to integrate anatomical and functional data, enabling more comprehensive and flex…
Nina Van Der Hoeven meets Roxana Mehran, winner of the Andreas Grüntzig Ethica Award 2026, the highest distinction in interventional cardiology.
At this stage of her career, after major contributions to clinical trials, guidelines, and the field at large, Roxana Mehran reflects on her journey. What…
In this interview, Flavio Ribichini and Sofie Brouwers discuss the evolving role of renal denervation in the management of hypertension. Now endorsed by major guidelines for patients with uncontrolled or resistant hypertension, the therapy is gaining wider acceptance in clinical practice.
They high…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da PCR, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
